Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2

Molecular Cancer Research

Volumn 6, Issue 6, 2008, Pages 1043-1051

  Mize, Gregory J ^a   Wang, Wenbin ^a   Takayama, Thomas K ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; KALLIKREIN; KALLIKREIN 2; KALLIKREIN 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROSTATE SPECIFIC ANTIGEN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SERINE PROTEINASE INHIBITOR; TISSUE KALLIKREIN;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYMOLOGY; MALE; METABOLISM; MOUSE; PATHOLOGY; PROSTATE TUMOR; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; APROTININ; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; KALLIKREINS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; PROSTATIC NEOPLASMS; RECEPTOR, PAR-1; RECEPTOR, PAR-2; RNA INTERFERENCE; RNA, MESSENGER; SERINE PROTEINASE INHIBITORS; TISSUE KALLIKREINS;

EID: 50349102480     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0096     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Clements J, Willemsen N, Myers S, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004;41:265-312.
3. Obiezu C, Diamandis E. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 2005;224:1-22.
4. Nelson PS, Gan L, Ferguson C, et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci U S A 1999;96:3114-9.
5. Takayama T, McMullen B, Nelson P, Matsumura M, Fujikawa K. Characterization of hK4 (prostase), a prostate specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001;40:15341-8.
6. Gao J, Collard R, Bui L, et al. Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate 2007;67:348-60.
7. Oikonomopoulou K, Hansen K, Saifeddine M, et al. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem 2006;387:817-24.
8. Coughlin S. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-64.
9. Macfarlane S, Seatter M, Kanke T, Hunter G, Plevin R. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-82.
10. Ossovskaya V, Bunnett N. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004;84:579-621.
11. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-68.
12. Nystedt S, Larsson AK, Aberg H, Sundelin J. The mouse proteinase-activated receptor-2 cDNA and gene. Molecular cloning and functional expression. J Biol Chem 1995;270:5950-55.
13. Ishihara H, Connolly AJ, Zeng D, et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997;386:502-6.
14. Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A 1998;95:6642-6.
15. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998;394:690-4.
16. Camerer E, Huang W, Coughlin S. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A 2000;97:5255-60.
17. D'Andrea M, Derian C, Santulli R, Andrade-Gordon P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 2001;158:2031-41.
18. Darmoul D, Marie J, Devaud H, Gratio V, Laburthe M. Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. Br J Cancer 2001;85:772-9.
19. Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998;4:909-14.
20. Henrikson K, Salazar S, Fenton J II, Pentecost B. Role of thrombin receptor in breast cancer invasiveness. Br J Cancer 1999;79:401-6.
21. Nierodzik M, Chen K, Takeshita K, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998;92:3694-700.
22. Black P, Mize G, Karlin P, et al. Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate 2007;67:743-56.
23. Kaushal V, Kohli M, Dennis R, et al. Thrombin receptor expression is upregulated in prostate cancer. Prostate 2006;66:273-82.
24. Chay C, Cooper C, Gendernalik J, et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 2002;60:760-5.
25. Greenberg D, Mize G, Takayama T. Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells. Biochemistry 2003;42:702-9.
26. Huang Y, Li J, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. ThrombHaemost 2001;86:1094-8.
27. Liu J, Schuff-Werner P, Steiner M. Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells. Biochem Biophys Res Commun 2006;343:183-9.
28. Tantivejkul K, Loberg R, Mawocha S, et al. PAR1-mediated NFκB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 2005;96:641-52.
29. Wilson S, Gallagher S, Warpeha K, Hawthorne S. Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. Prostate 2004;60:168-74.
30. Yin Y, Salah Z, Maoz M, et al. Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. FASEB J 2003;17:163-74.
31. Yoshida E, Verrusio E, Mihara H, Oh D, Kwaan H. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 1994;54:3300-4.
32. Yuan T, Lin M. Protease-activated receptor 1: a role in prostate cancer metastasis. Clin Prostate Cancer 2004;3:189-91.
33. Liu J, Bastian M, Kohlschein P, Schuff-Werner P, Steiner M. Expression of functional protease-activated receptor 1 in human prostate cancer cell lines. Urol Res 2003;31:163-8.
34. Shi X, Gangadharan B, Brass L, Ruf W, Mueller B. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004;2:395-402.
35. Sobel R, Sadar M. Cell lines used in prostate cancer research: a compendium of old and new lines - part 1 and 2. J Urol 2005;173:342-72.
36. Kollara A, Diamandis E, Brown T. Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells. J Steroid Biochem Mol Biol 2003;84:493-502.
37. Caunt C, Finch A, Sedgley K, McArdle C. Seven-transmembrane receptor signalling and ERK compartmentalization. Trends Endocrinol Metab2006;17:276-83.
38. Kumar A, Mikolajczyk S, Goel A, Millar L, Saedi M. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997;57:3111-4.
39. Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997;238:549-55.
40. Takayama TK, Carter CA, Deng T. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 2001;40:1679-87.
41. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen: activation by trypsin and by human glandular kallikrein. J Biol Chem 1997;272:21582-8.
42. Obiezu C, Shan S, Soosaipillai A, et al. Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clin Chem 2005;51:1432-42.
43. Klokk T, Kilander A, Xi Z, et al. Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res 2007;67:5221-30.
44. Xi Z, Klokk T, Korkmaz K, et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 2004;64:2365-70.
45. Dong Y, Bui L, Odorico D, et al. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms. Endocr Relat Cancer 2005;12:875-89.
46. Obiezu C, Soosaipillai A, Jung K, et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem 2002;48:1232-40.
47. Kumar A, Mikolajczyk S, Hill T, Millar L, Saedi M. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen induced LNCaP cells. Prostate 2000;44:248-54.
48. Camerer E, Kataoka H, Kahn M, Lease K, Coughlin S. Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem 2002;277:16081-7.
49. Liu J, Schuff-Werner P, Steiner M. Double transfection improves small interfering RNA-induced thrombin receptor (PAR-1) gene silencing in DU145 prostate cancer cells. FEBS Lett 2004;577:175-80.